Merck & Company Inc. (MRK)
NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:02 PM ET · Delayed 15 min
MRK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $329.65B
- P/E (TTM)
- 135.07
- Forward P/E
- 14.92
- EPS (TTM)
- $0.99
- Dividend yield
- 2.51% ($3.36)
- Ex-dividend date
- Sep 15, 2026
- 52-week range
- 96.06 – 156.92
- Day range
- 133.11 – 137.17
- Volume / Avg
- 15.61M / 9.81M
- Beta
- —
- Shares outstanding
- 2.47B
52-week range
MRK stock today
On Nov 20, MRK ended the session at $133.72, adding $0.91 (0.69%), versus the S&P 500's 3.70% decline. At this level, MRK sits in the middle of its 52-week range of $96.06 to $156.92: 14.8% below the high, set on Aug 25, 2026 and 39.2% above the low. MRK is up 27.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.8%.
At 135.1x trailing earnings, Merck trades above the peer-group median of 30.9x. Its forward P/E of 14.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Merck pays an annual dividend of $3.36 per share, a 2.51% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Merck
Company profileMerck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert M. Davis J.D.
- Headquarters
- Rahway, NJ
- Employees
- 73,000
- Website
- merck.com
Financial highlights
Full financialsIn fiscal 2025, Merck generated $65.01 billion in revenue, up 1.3% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $18.25 billion (+6.6% year over year), for a net margin of 28.1% versus a median of 24.5% in the prior 5 years. Gross margin was 74.8% (down from 76.3%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Growth | +1.31% | +6.74% | +1.40% | +21.72% | +17.31% |
| Net income | $18.25B | $17.12B | $365.00M | $14.52B | $13.05B |
| EPS (diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$161.53+20.80%
- Strong buy 5
- Buy 14
- Hold 9
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $2.58 vs $2.12
- Surprise
- +21.70%
Dividends
Dividend history- Annual dividend
- $3.36
- Dividend yield
- 2.51%
- Last payment
- $0.85
- Ex-dividend date
- Sep 15, 2026
MRK news
All MRK news- HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock DownNasdaqMRK, HALO, JNJ, ARGX
- Merck's Sac-TMT Extends Survival In Late-Stage Gastroesophageal Cancer Phase 2 TrialNasdaqMRK, BF.A
- Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027NasdaqMRNA, MRK, BMY, BNTX
- Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?NasdaqMRNA, PFE, MRK, BNTX
- Halozyme To Pursue Permanent Patent Case Against Merck After German Court Reverses InjunctionNasdaqHALO, MRK
- Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference TranscriptSeeking Alpha
- Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond MelanomaNasdaq
- Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to KnowNasdaq
Merck peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVSNovartis AG | 150.47 | -0.50% | $284.18B | vs MRK |
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs MRK |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs MRK |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs MRK |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs MRK |
| ABBVAbbVie Inc. | 286.20 | +0.94% | $505.89B | vs MRK |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs MRK |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs MRK |
Indexes, lists and sector
Index membership
Appears in lists
Merck stock FAQ
What is Merck's stock price today?
MRK last traded at $133.72 as of Nov 20, 4:02 PM EST, up 0.69% on the day. Prices are delayed at least 15 minutes.
Does Merck pay a dividend?
Yes. Merck pays $3.36 per share annually, a 2.51% yield. The most recent dividend of $0.85 had an ex-dividend date of Sep 15, 2026.
What is MRK's P/E ratio?
MRK trades at a trailing P/E ratio of 135.07 and a forward P/E of 14.92, compared with a median of 30.9 for its closest peers.
Is Merck in the S&P 500?
Yes. Merck (MRK) is a constituent of the S&P 500 index.
Who is Merck's CEO?
Mr. Robert M. Davis J.D. is the chief executive officer of Merck & Company Inc., which has about 73,000 employees.
Has MRK ever split its stock?
Yes. The most recent MRK stock split was a 1048-for-1000 split on Jun 3, 2021, one of 6 splits on record.
What is the MRK 52-week high?
The 52-week high for MRK is $156.92 and the 52-week low is $96.06. The stock is currently 14.8% below its high.